Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free sndx Stock Alerts $23.70 +0.63 (+2.73%) (As of 02:54 PM ET) Add Compare Share Share Today's Range$22.71▼$24.1950-Day Range$19.71▼$24.5752-Week Range$11.22▼$25.34Volume500,698 shsAverage Volume1.20 million shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$34.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Syndax Pharmaceuticals alerts: Email Address Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside45.8% Upside$34.42 Price TargetShort InterestHealthy9.80% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.54Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.70) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.94 out of 5 starsMedical Sector227th out of 939 stocksPharmaceutical Preparations Industry99th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.42, Syndax Pharmaceuticals has a forecasted upside of 45.8% from its current price of $23.60.Amount of Analyst CoverageSyndax Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.80% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 8.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 2.5 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows6 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Syndax Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.70) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesMarch 28, 2024 | msn.comSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDAMarch 28, 2024 | finance.yahoo.comSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 28, 2024 | seekingalpha.comSyndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite HopeMarch 28, 2024 | americanbankingnews.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC WainwrightMarch 28, 2024 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 28, 2024 | americanbankingnews.comInvestors Buy Large Volume of Put Options on Syndax Pharmaceuticals (NASDAQ:SNDX)March 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 27, 2024 | marketwatch.comSyndax Says Revumenib NDA Granted FDA Priority ReviewMarch 27, 2024 | markets.businessinsider.comSyndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute LeukemiaMarch 27, 2024 | msn.comFDA grants priority review for Syndax leukemia drug, sets action dateMarch 27, 2024 | finance.yahoo.comSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaMarch 21, 2024 | americanbankingnews.comJPMorgan Chase & Co. Raises Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $34.00March 18, 2024 | finanznachrichten.deSyndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 18, 2024 | finance.yahoo.comSyndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 16, 2024 | finance.yahoo.comSNDX Apr 2024 17.500 putMarch 13, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn SituationMarch 6, 2024 | markets.businessinsider.comBuy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory MilestonesMarch 3, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amid Strong Clinical Results and Solid Financial OutlookFebruary 28, 2024 | markets.businessinsider.comScotiabank Keeps Their Hold Rating on Syndax Pharmaceuticals (SNDX)February 27, 2024 | seekingalpha.comSyndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | benzinga.comSyndax Pharmaceuticals: Q4 Earnings InsightsFebruary 27, 2024 | finance.yahoo.comSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateFebruary 27, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees184Year FoundedN/APrice Target and Rating Average Stock Price Target$34.42 High Stock Price Target$45.00 Low Stock Price Target$23.00 Potential Upside/Downside+49.2%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.88% Return on Assets-44.00% Debt Debt-to-Equity RatioN/A Current Ratio10.00 Quick Ratio10.00 Sales & Book Value Annual Sales$139.71 million Price / Sales14.03 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.53Miscellaneous Outstanding Shares84,960,000Free Float80,972,000Market Cap$1.96 billion OptionableOptionable Beta1.03 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 53)CEO & Director Comp: $1.05MMr. Keith Alan Goldan CPA (Age 53)CFO, Treasurer & Chief Accounting Officer Comp: $649.07kMr. Luke J. Albrecht (Age 44)Senior VP, General Counsel & Secretary Comp: $605.82kDr. Catherine Madigan M.D. (Age 51)Chief Medical Officer Comp: $764.41kMr. Steve M. Sabus (Age 57)Chief Commercial Officer Comp: $523.44kDr. Neil Gallagher M.D.Ph.D., President, Head of Research & DevelopmentDr. Peter Ordentlich B.Sc. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 67)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 75)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderMore ExecutivesKey CompetitorsHarmony BiosciencesNASDAQ:HRMYGeronNASDAQ:GERNAmneal PharmaceuticalsNASDAQ:AMRXSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 746,293 shares on 3/18/2024Ownership: 0.878%Vanguard Group Inc.Bought 718,051 shares on 3/11/2024Ownership: 5.103%Wellington Management Group LLPSold 57,225 shares on 3/5/2024Ownership: 8.928%Goldman Sachs Group Inc.Sold 16,800 shares on 3/1/2024Ownership: 1.472%Virtu Financial LLCBought 11,948 shares on 2/26/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price target for 2024? 10 analysts have issued 12-month price objectives for Syndax Pharmaceuticals' stock. Their SNDX share price targets range from $23.00 to $45.00. On average, they anticipate the company's share price to reach $34.42 in the next twelve months. This suggests a possible upside of 45.8% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2024? Syndax Pharmaceuticals' stock was trading at $21.61 at the start of the year. Since then, SNDX stock has increased by 9.2% and is now trading at $23.60. View the best growth stocks for 2024 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by $0.01. During the same quarter last year, the business earned ($0.62) EPS. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.93%), Kynam Capital Management LP (6.67%), Vanguard Group Inc. (5.11%), Vanguard Group Inc. (5.10%), Avoro Capital Advisors LLC (4.98%) and Avidity Partners Management LP (4.66%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.